CLDX - Celldex Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
4,450
9,538
12,743
6,786
Cost of Revenue
-
-
-
-
Gross Profit
-
-
-
-
Operating Expenses
Research Development
43,540
66,449
96,171
102,726
Selling General and Administrative
16,540
19,269
25,003
35,979
Total Operating Expenses
60,080
85,942
122,070
139,702
Operating Income or Loss
-55,630
-76,404
-109,327
-132,916
Interest Expense
-
-
-
-
Total Other Income/Expenses Net
5,796
-75,545
-7,986
4,386
Income Before Tax
-49,834
-151,949
-117,313
-128,530
Income Tax Expense
0
-765
-24,282
-
Income from Continuing Operations
-49,834
-151,184
-93,031
-128,530
Net Income
-49,834
-151,184
-93,031
-128,530
Net Income available to common shareholders
-49,834
-151,184
-93,031
-128,530
Reported EPS
Basic
-
-14.48
-10.80
-19.05
Diluted
-
-14.48
-10.80
-19.05
Weighted average shares outstanding
Basic
-
10,442
8,570
6,769
Diluted
-
10,442
8,570
6,769
EBITDA
-
-72,603
-104,017
-128,824